Blood-brain barrier in drug discovery optimizing brain exposure of CNS drugs and minimizing brain side effects for peripheral drugs
(eBook)
Contributors
Published
Hoboken, New Jersey : John Wiley & Sons Inc., [2015].
Physical Desc
1 online resource (607 pages) : illustrations (some color)
Status
More Details
Format
eBook
Language
English
ISBN
9781118788547 (e-book)
Notes
Bibliography
Includes bibliographical references and index.
Description
"Focused on central nervous system (CNS) drug discovery efforts, this book educates drug researchers about the blood-brain barrier (BBB) so they can affect important improvements in one of the most significant - and most challenging - areas of drug discovery. Written by world experts to provide practical solutions to increase brain penetration or minimize CNS side-effects. Reviews state-of-the-art in silico, in vitro, and in vivo tools to assess brain penetration and advanced CNS drug delivery strategies. Covers BBB physiology, medicinal chemistry design principles, free drug hypothesis for the BBB, and transport mechanisms including passive diffusion, uptake/efflux transporters, and receptor-mediated processes. Highlights the advances in modelling BBB pharmacokinetics and dynamics relationships (PK/PD) and physiologically-based pharmacokinetics (PBPK). Discusses case studies of successful CNS and non-CNS drugs, lessons learned and paths to the market"--Provided by publisher.
Description
Loading Description...
Also in this Series
Checking series information...
Subjects
Other Subjects
Reviews from GoodReads
Loading GoodReads Reviews.
Citations
APA Citation, 7th Edition (style guide)
Di, L., & Kerns, E. H. (2015). Blood-brain barrier in drug discovery: optimizing brain exposure of CNS drugs and minimizing brain side effects for peripheral drugs . John Wiley & Sons Inc..
Chicago / Turabian - Author Date Citation, 17th Edition (style guide)Di, Li and Edward Harvel, Kerns. 2015. Blood-brain Barrier in Drug Discovery: Optimizing Brain Exposure of CNS Drugs and Minimizing Brain Side Effects for Peripheral Drugs. John Wiley & Sons Inc.
Chicago / Turabian - Humanities (Notes and Bibliography) Citation, 17th Edition (style guide)Di, Li and Edward Harvel, Kerns. Blood-brain Barrier in Drug Discovery: Optimizing Brain Exposure of CNS Drugs and Minimizing Brain Side Effects for Peripheral Drugs John Wiley & Sons Inc, 2015.
MLA Citation, 9th Edition (style guide)Di, Li, and Edward Harvel Kerns. Blood-brain Barrier in Drug Discovery: Optimizing Brain Exposure of CNS Drugs and Minimizing Brain Side Effects for Peripheral Drugs John Wiley & Sons Inc., 2015.
Note! Citations contain only title, author, edition, publisher, and year published. Citations should be used as a guideline and should be double checked for accuracy. Citation formats are based on standards as of August 2021.
Staff View
Grouped Work ID
a403454e-5b88-5604-ff03-7dfa3ce69bab-eng
Grouping Information
| Grouped Work ID | a403454e-5b88-5604-ff03-7dfa3ce69bab-eng |
|---|---|
| Full title | blood brain barrier in drug discovery optimizing brain exposure of cns drugs and minimizing brain side effects for peripheral drugs |
| Author | li di edward h kerns |
| Grouping Category | book |
| Last Update | 2022-06-07 21:23:19PM |
| Last Indexed | 2024-04-24 04:32:35AM |
Book Cover Information
| Image Source | syndetics |
|---|---|
| First Loaded | Jun 17, 2022 |
| Last Used | Apr 23, 2024 |
Marc Record
| First Detected | Aug 09, 2021 12:35:32 PM |
|---|---|
| Last File Modification Time | Nov 22, 2021 08:54:18 AM |
MARC Record
| LEADER | 05855nam a2200493 i 4500 | ||
|---|---|---|---|
| 001 | EBC1895601 | ||
| 003 | MiAaPQ | ||
| 006 | m E | | ||
| 007 | cr cnu|||||||| | ||
| 008 | 141015t20152015njuad ob 001 0 eng|d | ||
| 020 | |z 9781118788356 (hardback) | ||
| 020 | |a 9781118788547 (e-book) | ||
| 035 | |a (Sirsi) EBC1895601 | ||
| 035 | |a (Sirsi) EBC1895601 | ||
| 035 | |a (MiAaPQ)EBC1895601 | ||
| 035 | |a (Au-PeEL)EBL1895601 | ||
| 035 | |a (CaPaEBR)ebr11005763 | ||
| 035 | |a (CaONFJC)MIL688522 | ||
| 035 | |a (OCoLC)899941813 | ||
| 040 | |a MiAaPQ|b eng|c MiAaPQ|d MiAaPQ|e rda|e pn | ||
| 050 | 4 | |a RM315|b .B56 2015 | |
| 082 | 0 | |a 615.7/8|2 23 | |
| 245 | 0 | 0 | |a Blood-brain barrier in drug discovery |h [eBook]:|b optimizing brain exposure of CNS drugs and minimizing brain side effects for peripheral drugs /|c edited by Li Di, Edward H. Kerns. |
| 264 | 1 | |a Hoboken, New Jersey :|b John Wiley & Sons Inc.,|c [2015] | |
| 264 | 4 | |c ©2015 | |
| 300 | |a 1 online resource (607 pages) :|b illustrations (some color) | ||
| 336 | |a text|2 rdacontent | ||
| 337 | |a computer|2 rdamedia | ||
| 338 | |a online resource|2 rdacarrier | ||
| 504 | |a Includes bibliographical references and index. | ||
| 505 | 8 | |a Machine generated contents note: Summary List of Chapters1. Overview/Introduction / Li Di (Pfizer Inc.), Edward H. Kerns (Pharmacokinetics of Brain Exposure)2. Pharmacokinetics of CNS penetration / Andreas Reichel (Bayer)3. Free Drug Hyposthesis for CNS Drug Candidates / Xingrong Liu (Genentech)4. Species Differences and impact of desease state on BBB / Jean-Marie Nicolas (UCB Pharma S.A.)Mechanisms of Drugs Across the Blood-Brain Barrier5. Passive diffusion permeability of the BBB - examples and SAR / Phil Jeffrey (GSK)6. Efflux transport at the BBB - examples and SAR / Jerome Hochman (Merck)7. Uptake transport at the BBB - examples and SAR / Zack Cheng (AstraZeneca)8. Uptake of proteins and antibodies at the BBB / William Pardridge (UCLA)Predicting and Measuring Brain Exposure of Drugs9. In silico tools for assessing brain exposure / Hongming Chen (AstraZeneca)10. In vitro assays for assessing BBB permeability - vascular cells, artificial membranes, brain slice, cell uptake / Winfried Neuhaus (University of Vienna)11. Human-based in vitro endothelial cell models / Eric Shusta (University of Wisconsin)12. In vitro assays for assessing brain binding / Li Di (Pfizer)13. In vivo studies of brain exposure / Edward H. Kerns14. PBPK models for BBB / Elizabeth de Lange (Leiden University)15. PK/PD modeling of CNS drug candidates / Johan Gabrielsson (Swedish University)16. Microdialysis to assess free drug concentration in brain / William Kielbasa (Lilly)17. Imaging technique for CNS drug discovery / Lei Zhang (Pfizer Inc.)Modulating Brain Penetration of Leads During Drug Discovery18. Designing CNS drugs for optimal brain exposure / Zoran Rankovic (Lilly)19. Case studies of CNS drug optimization - medicinal chemistry and CNS biology perspectives / Kevin J. Hodgetts (Harvard NeuroDiscovery Center)20. Designing peripheral drugs for minimal brain exposue / Peter Bungay (Pfizer)21. Case studies of non-CNS drugs to minimize brain penetration - Nonsudative antihistamines / Andrew Crowe (Curtin University)Case Studies in CNS Drug Discovery22. Case study 1 on discovery of a successful CNS drug - Fycompa (AMPA Receptor Antagonist) / Andrew Satlin and Antonio Laurenza (Eisai)23. Case study 2 on discovery of a successful CNS drug - Vortioxetine (Serotonin Modulator and Stimulator) / Benny Bang-Andersen (Lundbeck)Drug Delivery Techniques to CNS24. Brain delivery using nanotechnology / Xinguo Jiang (Fudan University)25. Intranasal delivery to CNS / Lisbeth Illum (University of Nottingham)Future Prospective in Blood Brain Barrier Advancement26. Conclusion Remarks / Joan Abbott (King's College). | |
| 520 | |a "Focused on central nervous system (CNS) drug discovery efforts, this book educates drug researchers about the blood-brain barrier (BBB) so they can affect important improvements in one of the most significant - and most challenging - areas of drug discovery. Written by world experts to provide practical solutions to increase brain penetration or minimize CNS side-effects. Reviews state-of-the-art in silico, in vitro, and in vivo tools to assess brain penetration and advanced CNS drug delivery strategies. Covers BBB physiology, medicinal chemistry design principles, free drug hypothesis for the BBB, and transport mechanisms including passive diffusion, uptake/efflux transporters, and receptor-mediated processes. Highlights the advances in modelling BBB pharmacokinetics and dynamics relationships (PK/PD) and physiologically-based pharmacokinetics (PBPK). Discusses case studies of successful CNS and non-CNS drugs, lessons learned and paths to the market"--Provided by publisher. | ||
| 588 | |a Description based on print version record. | ||
| 650 | 0 | |a Brain|x Effect of drugs on. | |
| 650 | 0 | |a Blood-brain barrier. | |
| 655 | 4 | |a Electronic books. | |
| 700 | 1 | |a Di, Li|e editor. | |
| 700 | 1 | |a Kerns, Edward Harvel,|e editor. | |
| 776 | 0 | 8 | |i Print version:|t Blood-brain barrier in drug discovery : optimizing brain exposure of CNS drugs and minimizing brain side effects for peripheral drugs.|d Hoboken, New Jersey : John Wiley & Sons Inc., [2015]|z 9781118788356|w (DNLM)101643550|w (DLC)11005763 |
| 797 | 2 | |a ProQuest (Firm) | |
| 856 | 4 | 0 | |u http://ebookcentral.proquest.com/lib/yavapai-ebooks/detail.action?docID=1895601|x Yavapai College|y Yavapai College users click here to access |
| 856 | 4 | 0 | |u http://ebookcentral.proquest.com/lib/prescottcollege-ebooks/detail.action?docID=1895601|x Prescott College|y Prescott College users click here to access |
| 856 | 4 | 0 | |u http://ebookcentral.proquest.com/lib/yln-ebooks/detail.action?docID=1895601|x Yavapai Library Network|y All other users click here to access |
| 945 | |a E-Book | ||
